Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 6

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 1
Chunk 6
---
110 
  
    Net cash used in operating activities 
     (3,373,654) 
     (3,962,095)

    Cash flows provided by (used in) financing activities: 

    Proceeds from the issuance of common stock, net 
     3,744,466  
     3,539,907 
  
    Proceeds from the issuance of common stock upon Class A and Class B warrant exercises 
     –  
     1,844,400 
  
    Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units 
     (8,701) 
     (8,910)
  
    Net cash provided by financing activities 
     3,735,765  
     5,375,397 

    Effect of exchange rate on changes on cash 
     (9,244) 
     3,795 

    Net increase in cash, cash equivalents and restricted cash 
     352,867  
     1,417,097 

    Cash, cash equivalents and restricted cash at beginning of period 
     5,599,074  
     5,529,484 

    Cash, cash equivalents and restricted cash at end of period 
    $5,951,941  
    $6,946,581 

    Supplemental disclosures of cash flow information: 

    Supplemental disclosures of non-cash investing and financing activities: 

    Par value of shares issued for vested restricted stock units 
    $2  
    $1 

    Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets: 

    Cash and cash equivalents 
    $5,853,493  
    $6,859,075 
  
    Restricted cash 
     98,448  
     87,506 
  
    Cash, cash equivalents and restricted cash 
    $5,951,941  
    $6,946,581 

The accompanying notes are an integral part
of these condensed consolidated financial statements.

 7 

AETHLON MEDICAL, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

September 30, 2025

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION ORGANIZATION

Aethlon Medical, Inc., or Aethlon, the Company,
we